Zydus receives final approval from USFDA for Perphenazine Tablets USP

April 7, 2020 Listing Department Code: 532321 BSE Limited P J Towers, Dalal Street, Fort, Mumbai – 400001 Listing Department Code: CADILAHC NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051 Re.: Press Release Dear Sir / Madam, Please find enclosed a Press Release dated April 7, 2020 titled “Zydus receives final approval from USFDA for Perphenazine Tablets USP”. The contents of the Press Release give full details. Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large. Thanking you, Yours faithfully, For, CADILA HEALTHCARE LIMITED DHAVAL N. SONI COMPANY SECRETARY Encl.: As above Zydus receives final approval from USFDA for Perphenazine Tablets USP Ahmedabad, April 7, 2020 Zydus Cadila has received final approval from the USFDA to market Perphenazine Tablets USP, 2 mg, 4 mg, 8 mg and 16 mg. (US RLD: Trilafon® Tablets) This medication is indicated for the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. The drug will be manufactured at the group’s formulation manufacturing facility at Baddi. The group now has 284 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗